Company

G1 Therapeutics

Rocket Ship Rating

Rocket Ship Rating: 89 out of 100

Next Generation Cancer Therapies

Also known as G1 Therapeutics, Inc.

Biotech & therapeutics

Status: Acquiredas of 2026-09-17Source (opens in a new tab)
Business model: B2B
Legal name: G1 Therapeutics, Inc.

Open relationship map

Claim, correct or request removal

Record updated 28 September 2026

About

Our mission is clear: to develop and deliver next generation therapies that improve the lives and outcomes of people living with cancer.

Funding snapshot

Total raised: $81.1MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
Latest round: Round, $50M2016-04-27

Funding rounds

Round, 2016: $50M2016-04-27, SEC form D sold, 21 investors
Round, 2015: $16.5M2015-02-04, SEC form D sold, 10 investors
Round, 2013: $12.6M2013-10-08, SEC form D sold, 8 investors
Round, 2013: $1.2M2013-04-03, SEC form D sold, 6 investors
Round, 2012: $763K2012-08-27, SEC form D sold, 4 investors

About the company

Status notes: G1 is now a subsidiary of Pharmacosmos Therapeutics

Exit

Acquisition: 2024